Phenergan and Diprivan drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Phenergan (promethazine hydrochloride) and Diprivan (propofol). Common drug interactions include oedema peripheral among females and thrombocytopenia among males.

The phase IV clinical study analyzes what interactions people have when they take Phenergan and Diprivan. It is created by eHealthMe based on reports of 52 people who take the same drugs from the FDA, and is updated regularly.

What is Phenergan?

Phenergan has active ingredients of promethazine hydrochloride. It is often used in nausea. eHealthMe is studying from 25,312 Phenergan users. Check the latest studies of Phenergan.

What is Diprivan?

Diprivan has active ingredients of propofol. eHealthMe is studying from 6,496 Diprivan users. Check the latest studies of Diprivan.



On Aug, 11, 2026

52 people who take Phenergan and Diprivan together, and have interactions are studied.

Phenergan and Diprivan drug interactions.

What are the common drug interactions of Phenergan and Diprivan, by gender? *:

female:

  1. Oedema peripheral (superficial swelling)
  2. Pain
  3. Pain in extremity
  4. Renal failure (kidney dysfunction)
  5. Abdominal infection
  6. Alanine aminotransferase increased
  7. Aspartate aminotransferase increased
  8. Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
  9. Bradyarrhythmia (heart slowness)
  10. Bradycardia (abnormally slow heart action)

male:

  1. Thrombocytopenia (decrease of platelets in blood)
  2. Sepsis (a severe blood infection that can lead to organ failure and death)
  3. Renal failure (kidney dysfunction)
  4. Abdominal pain upper
  5. Bacteraemia (presence of bacteria in the blood)
  6. Blood creatinine increased
  7. Drug effect decreased
  8. Hypotension (abnormally low blood pressure)
  9. Pseudomonas infection (pseudomonas infection is caused by a bacterium, pseudomonas aeruginosa)
  10. Respiratory failure (inadequate gas exchange by the respiratory system)

What are the common drug interactions of Phenergan and Diprivan, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

  1. Alanine aminotransferase increased
  2. Aspartate aminotransferase increased

10-19:

  1. Abdominal pain
  2. Alanine aminotransferase increased
  3. Aspartate aminotransferase increased
  4. Gamma-glutamyltransferase increased
  5. Headache (pain in head)
  6. Hepatic trauma (liver injury)
  7. Hepatitis (inflammation of the liver)
  8. Hypersensitivity

20-29:

  1. Abdominal distension
  2. Aggression
  3. Back pain
  4. Blood cholesterol increased
  5. Bradyarrhythmia (heart slowness)
  6. Bradycardia (abnormally slow heart action)
  7. Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
  8. Cardiac flutter (abnormal heart rhythm)
  9. Cardio-respiratory arrest (sudden dysfunction of heart and lungs)
  10. Chest tightness

30-39:

  1. Breast enlargement
  2. Menstruation irregular
  3. Pelvic pain
  4. Stevens-johnson syndrome (an immune-complex-mediated hypersensitivity disorder. it ranges from mild skin and mucous membrane lesions to a severe)
  5. Abdominal pain
  6. Cavernous sinus thrombosis (formation of a blood clot in brain)
  7. Confusional state
  8. Headache (pain in head)
  9. Mental status changes (general changes in brain function, such as confusion, amnesia (memory loss), loss of alertness, loss of orientation)
  10. Right ventricular failure (right half of the heart fails to work)

40-49:

  1. Abdominal distension
  2. Abdominal pain
  3. Device dislocation
  4. Dysmenorrhoea (painful menstruation)
  5. Fatigue (feeling of tiredness)
  6. Lymphocyte count decreased
  7. Menorrhagia (an abnormally heavy bleeding and prolonged menstrual period at regular intervals)
  8. Migraine (headache)
  9. Uterine haemorrhage (uterine bleeding)
  10. Sepsis (a severe blood infection that can lead to organ failure and death)

50-59:

  1. Breast cancer in situ
  2. Breast mass
  3. Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
  4. Burning sensation
  5. Carotid bruit (sound heard over the carotid artery area during auscultation)
  6. Chronic obstructive pulmonary disease (a progressive disease that makes it hard to breathe)
  7. Colonic polyp (extra part of colon tissue grow in intestine)
  8. Deep vein thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis)
  9. Diverticulum intestinal (a pouch that is attached to the first part of the small intestine)
  10. Dizziness

60+:

  1. Sepsis (a severe blood infection that can lead to organ failure and death)
  2. Unresponsive to stimuli
  3. Blood creatinine increased
  4. Cardiac failure
  5. Dyspnoea (difficult or laboured respiration)
  6. Fluid retention (an abnormal accumulation of fluid in the blood)
  7. General physical health deterioration (weak health status)
  8. Pyrexia (fever)
  9. Acute respiratory distress syndrome
  10. Cytokine storm (over-protective immune response that can actually be fatal)

What are the existing conditions these people have? *

  1. Pain: 9 people, 17.31%
  2. Depression: 6 people, 11.54%
  3. Constipation: 4 people, 7.69%
  4. Muscle Spasms (muscle contraction): 3 people, 5.77%
  5. Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 3 people, 5.77%
  6. Migraine Without Aura (headache without neurological problems): 3 people, 5.77%
  7. Hypotension (abnormally low blood pressure): 3 people, 5.77%
  8. Hypertonic Bladder (bladder-storage function that causes a sudden urge to urinate): 3 people, 5.77%
  9. High Blood Pressure: 3 people, 5.77%
  10. Heart Attack: 3 people, 5.77%

* Approximation only. Some reports may have incomplete information.

Do you take Phenergan and Diprivan?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Phenergan and Diprivan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Phenergan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Diprivan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Phenergan and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Diprivan and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on promethazine hydrochloride and propofol (the active ingredients of Phenergan and Diprivan, respectively), and Phenergan and Diprivan (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: